Prateek Tanmay
3 min readPuneJul 16, 2026 11:29 PM IST
The Gates Medical Research Institute (Gates MRI) has partnered with the Serum Institute of India Private Limited (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate. Currently in a Phase 3 clinical trial, M72/AS01E has the potential to be the first new TB vaccine to be introduced in more than a century – a potential breakthrough against a disease that remains the world’s leading infectious cause of death and disproportionately impacts low and middle-income countries, according to an official statement issued on Thursday.
This partnership marks a critical step toward ensuring that, if approved, the vaccine can be produced at scale and made available to adults and adolescents in countries with a high TB burden as soon as possible. SII was selected based on its record of producing WHO-prequalified vaccines, affordably and at scale, and meeting stringent global quality and regulatory standards, according to the statement.
With this partnership, Gates MRI and SII will begin the process of transferring the technology and know-how required to manufacture the antigen and enable future large-scale production of M72/AS01E. SII expects to invest more than US$100 million of its own resources to strengthen manufacturing readiness and capacity building to support potential future supply. GSK, the original developer of the vaccine, will supply the AS01E adjuvant. Initiating this work well ahead of Phase 3 trial results is a deliberate strategy to ensure readiness to produce and distribute the vaccine and begin meeting global demand as quickly as possible, should the trial be successful and regulatory approvals be granted.
Gates MRI is sponsoring the Phase 3 clinical trial of M72/AS01E, with funding from the Gates Foundation and Wellcome. The double-blind, randomized trial, which started in March 2024, reached full enrollment in April 2025, of 20,000 participants in South Africa, Kenya, Malawi, Zambia, and Indonesia across 54 sites.
In a Phase 2b randomized, double-blind, placebo-controlled trial with 3,575 participants sponsored by the vaccine’s developer, GSK, M72/AS01E was shown to provide approximately 50% protection against progression to active pulmonary TB over a three-year follow-up period in TB-infected HIV-negative adults aged 18 to 50 years. The World Health Organization estimates a vaccine with this efficacy profile could prevent 76 million new TB cases, save 8.5 million lives, and save $41.5 billion for TB-affected households over 25 years.
